New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC

- A Total of 13 Abstracts for Eight Compounds Being Presented -

SOUTH SAN FRANCISCO, Calif., October 08, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. today announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, VEGFR2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

"With 13 abstracts covering eight clinical-stage compounds, the 2007 AACR-NCI-EORTC meeting is an important opportunity to highlight the breadth and depth of our pipeline," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Critical to our goal of building a world-class oncology franchise is the rapid advancement of the 14 compounds currently in the clinic and the continued ability to advance additional compounds into development. We believe our strong presence at this meeting is evidence of our productivity. Three of the phase 1 compounds that will be discussed were preclinical compounds at this time last year and we will present phase 2 data from trials that were initiated less than 18 months ago."

Exelixis will hold a briefing for investors and analysts on Wednesday, October 24, 2007, from 6:00-8:00 p.m. PDT / 9:00-11:00 p.m. EDT. During the briefing, Exelixis management will review data for XL647, XL880 and XL184, in addition to other Exelixis compounds. This webcast may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com. An archive of the webcast will be available until 8:59 p.m. PST/11:59 p.m. EST on November 24, 2007. Access numbers for the replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international). The replay passcode is 86296035.

    The full list of abstracts to be presented at the meeting follows:


    Phase 2 Clinical Abstracts

    -- A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients

       (pts) with papillary renal carcinoma (PRC) (Abstract #B249)

    -- A Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

       (NSCLC) Enriched for Presence of EGFR Mutations (Abstract #B124)



    Phase 1 Clinical Abstracts

    -- A phase 1 dose-escalation study of the safety and pharmacokinetics (PK)

       of XL184, a VEGFR and MET kinase inhibitor, administered orally to

       patients (pts) with advanced malignancies (Abstract #A152)

    -- A phase I dose-escalation study of the safety, pharmacokinetics, and

       pharmacodynamics of XL820 administered orally daily (QD) or twice daily

       (BID) to patients (pts) with solid malignancies (Abstract #B69)

    -- Targeting aberrant PI3K pathway signaling with XL147, a potent,

       selective and orally bioavailable PI3K inhibitor (Abstract #C205)

    -- Biomarker development for XL765, a potent and selective oral dual

       inhibitor of PI3K and mTOR currently being administered to patients in

       a Phase I clinical trial (Abstract #B265)

    -- A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a

       novel spectrum selective kinase inhibitor, administered orally daily to

       patients with advanced solid malignancies (ASM) (Abstract #B242)

    -- A Phase I dose-escalation study of the safety, pharmacokinetics (PK)

       and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor,

       administered daily to patients (pts) with advanced malignancies

       (Abstract #B248)



    Preclinical Abstracts

    -- XL820 inhibits mutated forms of KIT associated with drug resistance

       (Abstract #B237)

    -- In vitro and in vivo potentiation of cytotoxic therapy by XL844, an

       orally bioavailable inhibitor of Chk1 and Chk2 (Abstract #B228)

    -- XL518, a Potent Selective Orally Bioavailable MEK1 Inhibitor,

       Downregulates the RAS/RAF/MEK/ERK Pathway In Vivo, Resulting in Tumor

       Growth Inhibition and Regression in Pre-Clinical Models (Abstract

       #C209)

    -- Potentiating the antitumor effects of chemotherapy with the selective

       PI3K inhibitor XL147 (Abstract #C199)

    -- XL765 targets tumor growth, survival, and angiogenesis in preclinical

       models by dual inhibition of PI3K and mTOR (Abstract #B250)


About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

CONTACT: Charles Butler, Director, Investor Relations, +1-650-837-7277,, or Hal Mackins, +1-650-837-7012,, both of Exelixis, Inc. cbutler@exelixis.com hmackins@exelixis.com

Web site: http://www.exelixis.com/

Ticker Symbol: (NASDAQ-NMS:EXEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007

View comments

Hide
(web2)